{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:52:59Z","timestamp":1781671979369,"version":"3.54.5"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:00:00Z","timestamp":1779580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014823","name":"VGH & UBC Hospital Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000245","name":"Michael Smith Health Research BC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.gore.2026.102123","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T23:36:34Z","timestamp":1780356994000},"page":"102123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Granulosa cell tumors and menopausal hormone therapy: A narrative review"],"prefix":"10.1016","volume":"65","author":[{"given":"Abigail","family":"Shore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanlan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Hewins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Huntsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesa M.","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gore.2026.102123_b0005","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1210\/er.2011-0014","article-title":"Molecular pathogenesis of granulosa cell tumors of the ovary","volume":"33","author":"Jamieson","year":"2012","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.gore.2026.102123_b0010","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/cjp2.198","article-title":"Adult\u2010type granulosa cell tumor of the ovary: a FOXL2 \u2010centric disease","volume":"7","author":"Pilsworth","year":"2021","journal-title":"The Journal of Pathology CR"},{"key":"10.1016\/j.gore.2026.102123_b0015","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ygyno.2011.10.015","article-title":"A long-term follow-up study of 176 cases with adult-type ovarian granulosa cell tumors","volume":"124","author":"Sun","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2026.102123_b0020","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1136\/ijgc-2022-003854","article-title":"Adult ovarian granulosa cell tumors: analysis of outcomes and risk factors for recurrence","volume":"33","author":"Plett","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.gore.2026.102123_b0025","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejogrb.2018.04.002","article-title":"Granulosa cell tumor of ovary: a systematic review of recent evidence","volume":"225","author":"Levin","year":"2018","journal-title":"European Journal of Obstetrics & Gynecology and Reproductive Biology"},{"key":"10.1016\/j.gore.2026.102123_b0030","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/IGC.0000000000000304","article-title":"Clinical characteristics and survival of patients with an adult-type ovarian granulosa cell tumor a 56-year single-center experience","volume":"25","author":"Bryk","year":"2015","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.gore.2026.102123_b0035","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ygyno.2014.06.021","article-title":"Development and internal validation of a prognostic model to predict recurrence free survival in patients with adult granulosa cell tumors of the ovary","volume":"134","author":"Van Meurs","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2026.102123_b0040","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/ijgc-2020-001217","article-title":"European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis","volume":"30","author":"Rees","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.gore.2026.102123_b0045","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ajog.2019.08.043","article-title":"Management of genitourinary syndrome of menopause in female cancer patients: a focus on vaginal hormonal therapy","volume":"222","author":"Crean-Tate","year":"2020","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.gore.2026.102123_b0050","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1080\/13697137.2024.2418503","article-title":"Systemic hormone therapy after breast and gynecological cancers: an italian expert group consensus opinion","volume":"28","author":"Cagnacci","year":"2025","journal-title":"Climacteric"},{"key":"10.1016\/j.gore.2026.102123_b0055","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/ijc.29532","article-title":"The clinical utility of serum anti\u2010 M \u00fcllerian hormone in the follow\u2010up of ovarian adult\u2010type granulosa cell tumors\u2014A comparative study with inhibin B","volume":"137","author":"F\u00e4rkkil\u00e4","year":"2015","journal-title":"Intl Journal of Cancer"},{"key":"10.1016\/j.gore.2026.102123_b0060","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ejogrb.2020.08.011","article-title":"Diagnostic value of Anti-Mullerian hormone in ovarian granulosa cell tumor: a meta-analysis","volume":"253","author":"Chen","year":"2020","journal-title":"European Journal of Obstetrics & Gynecology and Reproductive Biology"},{"key":"10.1016\/j.gore.2026.102123_b0065","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00428-024-03854-0","article-title":"An extensive immunohistochemical analysis of 290 ovarian adult granulosa cell tumors with 29 markers","volume":"485","author":"N\u011bmejcov\u00e1","year":"2024","journal-title":"Virchows Arch."},{"key":"10.1016\/j.gore.2026.102123_b0070","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ygyno.2023.07.007","article-title":"Clinicopathological analysis of patients with molecularly confirmed stage I adult granulosa cell tumors and prediction of recurrence","volume":"176","author":"Liu","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2026.102123_b0075","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/PGP.0000000000001032","volume":"43","author":"Moh","year":"2024","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.gore.2026.102123_b0080","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygyno.2014.03.573","article-title":"Hormone therapy in ovarian granulosa cell tumors: a systematic review","volume":"134","author":"Van Meurs","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2026.102123_b0085","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ygyno.2021.07.024","article-title":"A phase 2 study of anastrozole in patients with oestrogen receptor and\/progesterone receptor positive recurrent\/metastatic granulosa cell tumours\/sex-cord stromal tumours of the ovary: the PARAGON\/ANZGOG 0903 trial","volume":"163","author":"Banerjee","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2026.102123_b0090","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqad063","article-title":"ER\u03b2 in granulosa cell tumors and its clinical potential","volume":"164","author":"Birgersson","year":"2023","journal-title":"Endocrinology"},{"key":"10.1016\/j.gore.2026.102123_b0095","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/mrd.22285","article-title":"Cytokines in ovarian folliculogenesis, oocyte maturation and luteinisation","volume":"81","author":"Field","year":"2014","journal-title":"Molecular Reproduction Devel"},{"key":"10.1016\/j.gore.2026.102123_b0100","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s00018-023-04709-8","article-title":"The role of amphiregulin in ovarian function and disease","volume":"80","author":"Fang","year":"2023","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.gore.2026.102123_b0105","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0303-7207(94)90278-X","article-title":"Follicular oestrogen synthesis: the \u2018two-cell, two-gonadotrophin\u2019 model revisited","volume":"100","author":"Hillier","year":"1994","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.gore.2026.102123_b0110","doi-asserted-by":"crossref","unstructured":"Barbieri, R. L. The Endocrinology of the Menstrual Cycle. in Human Fertility (eds Rosenwaks, Z. & Wassarman, P. M.) vol. 1154 145\u2013169 (Springer New York, New York, NY, 2014).","DOI":"10.1007\/978-1-4939-0659-8_7"},{"key":"10.1016\/j.gore.2026.102123_b0115","first-page":"117","article-title":"Ovarian follicular and luteal physiology","volume":"22","author":"Channing","year":"1980","journal-title":"Int. Rev. Physiol."},{"key":"10.1016\/j.gore.2026.102123_b0120","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3390\/ijms23010512","article-title":"Estradiol signaling at the heart of folliculogenesis: its potential deregulation in human ovarian pathologies","volume":"23","author":"Chauvin","year":"2022","journal-title":"IJMS"},{"key":"10.1016\/j.gore.2026.102123_b0125","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12253-018-00569-x","article-title":"Hormone replacement therapy in cancer survivors \u2013 review of the literature","volume":"26","author":"Deli","year":"2020","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.gore.2026.102123_b0130","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ygyno.2019.01.016","article-title":"The association between progesterone receptor expression and survival in women with adult granulosa cell tumors","volume":"153","author":"Puechl","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2026.102123_b0135","doi-asserted-by":"crossref","first-page":"IJE08","DOI":"10.2217\/ije-2017-0021","article-title":"Ovarian adult-type granulosa cell tumor: focusing on endocrine-based therapies","volume":"5","author":"Yang","year":"2018","journal-title":"Int. J. Endo. Oncol."},{"key":"10.1016\/j.gore.2026.102123_b0140","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/07853890.2017.1294760","article-title":"Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary","volume":"49","author":"F\u00e4rkkil\u00e4","year":"2017","journal-title":"Ann. Med."},{"key":"10.1016\/j.gore.2026.102123_b0145","doi-asserted-by":"crossref","first-page":"20158","DOI":"10.1038\/s41598-022-24680-x","article-title":"Cooperative effects of oocytes and estrogen on the forkhead box L2 expression in mural granulosa cells in mice","volume":"12","author":"Ito","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.gore.2026.102123_b0150","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaa034","article-title":"Functional profiling of FSH and estradiol in ovarian granulosa cell tumors","volume":"4","author":"Haltia","year":"2020","journal-title":"J. Endocr. Soc."},{"key":"10.1016\/j.gore.2026.102123_b0155","doi-asserted-by":"crossref","first-page":"263","DOI":"10.36401\/JIPO-23-40","article-title":"Advanced granulosa cell tumors of the ovary: a review with a focus on current and novel therapeutic approaches","volume":"7","author":"Salkeni","year":"2024","journal-title":"Journal of Immunotherapy and Precision Oncology"},{"key":"10.1016\/j.gore.2026.102123_b0160","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/carcin\/bgv041","article-title":"17\u03b2-estradiol inhibits spreading of metastatic cells from granulosa cell tumors through a non-genomic mechanism involving GPER1","volume":"36","author":"Fran\u00e7ois","year":"2015","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.gore.2026.102123_b0165","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/path.5843","article-title":"Estradiol promotes cell survival and induces Greb1 expression in granulosa cell tumors of the ovary through an ER\u03b1 -dependent mechanism","volume":"256","author":"Cluzet","year":"2022","journal-title":"J. Pathol."},{"key":"10.1016\/j.gore.2026.102123_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2024.106526","article-title":"Estrogen receptor beta expression and role in cancers","volume":"242","author":"Monteiro","year":"2024","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.gore.2026.102123_b0175","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ygyno.2018.05.013","article-title":"Estrogen receptor \u03b2: potential target for therapy in adult granulosa cell tumors?","volume":"150","author":"Ciucci","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2026.102123_b0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046270","article-title":"The Transcriptional Targets of Mutant FOXL2 in Granulosa Cell Tumours","volume":"7","author":"Rosario","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.gore.2026.102123_b0185","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.maturitas.2009.11.017","article-title":"Hormone replacement after gynaecological cancer","volume":"65","author":"Singh","year":"2010","journal-title":"Maturitas"},{"key":"10.1016\/j.gore.2026.102123_b0190","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejca.2019.04.018","article-title":"Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancers","volume":"116","author":"Rousset-Jablonski","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.gore.2026.102123_b0195","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/20533691241286666","article-title":"British Gynaecological Cancer Society and British Menopause Society guidelines: Management of menopausal symptoms following treatment of gynaecological cancer","volume":"30","author":"Taylor","year":"2024","journal-title":"Post Reprod Health"},{"key":"10.1016\/j.gore.2026.102123_b0200","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejogrb.2024.06.025","article-title":"British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: Recommendations for practice update 2024","volume":"300","author":"Moss","year":"2024","journal-title":"European Journal of Obstetrics & Gynecology and Reproductive Biology"},{"key":"10.1016\/j.gore.2026.102123_b0205","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ygyno.2009.06.040","article-title":"The epidemiology of ovarian granulosa cell tumors: a case-control study","volume":"115","author":"Boyce","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2026.102123_b0210","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.ygyno.2021.09.013","article-title":"Parity, menopausal hormone therapy, and risk of ovarian granulosa cell tumor \u2013 a population-based case-control study","volume":"163","author":"Bryk","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2026.102123_b0215","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1158\/1541-7786.MCR-22-0623","article-title":"Comparative tumor microenvironment analysis of primary and recurrent ovarian granulosa cell tumors","volume":"21","author":"Khlebus","year":"2023","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.gore.2026.102123_b0220","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/PAT.0b013e328359d636","article-title":"Immunohistochemical expression and prognostic significance of oestrogen receptor-alpha, oestrogen receptor-beta, and progesterone receptor in stage 1 adult-type granulosa cell tumour of the ovary","volume":"44","author":"Hutton","year":"2012","journal-title":"Pathology"},{"key":"10.1016\/j.gore.2026.102123_b0225","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/IGC.0000000000000659","article-title":"Prognostic factors in adult granulosa cell tumor: a long follow-up at a single center","volume":"26","author":"Karalok","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.gore.2026.102123_b0230","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00404-021-06305-2","article-title":"Prognostic predictors in recurrent adult granulosa cell tumors of the ovary: a systematic review and meta-analysis","volume":"306","author":"Inzani","year":"2022","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.gore.2026.102123_b0235","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ygyno.2026.04.018","article-title":"Estrogen hormone therapy use in ovarian cancer patients under age 60 at diagnosis","volume":"209","author":"Lukey","year":"2026","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2026.102123_b0240","article-title":"Hormone replacement therapy for women previously treated for endometrial cancer","volume":"2018","author":"Edey","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.gore.2026.102123_b0245","doi-asserted-by":"crossref","first-page":"506","DOI":"10.18632\/oncotarget.13471","article-title":"Is the positivity of estrogen receptor or progesterone receptor different between type 1 and type 2 endometrial cancer?","volume":"8","author":"Shen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.gore.2026.102123_b0250","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1746-1596-9-77","article-title":"Distribution of estrogen and progesterone receptors isoforms in endometrial cancer","volume":"9","author":"Kreizman-Shefer","year":"2014","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.gore.2026.102123_b0255","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/1471-0528.17331","article-title":"The effect of progestin therapy in advanced and recurrent endometrial cancer: a systematic review and meta\u2010analysis","volume":"130","author":"Van Weelden","year":"2023","journal-title":"BJOG"},{"key":"10.1016\/j.gore.2026.102123_b0260","doi-asserted-by":"crossref","first-page":"S1160","DOI":"10.1016\/j.annonc.2020.08.2258","article-title":"LBA28 a randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) advanced\/recurrent endometrial cancer (EC): NSGO-PALEO \/ ENGOT-EN3 trial","volume":"31","author":"Mirza","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.gore.2026.102123_b0265","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/ijgc-2023-005189","article-title":"A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trial","volume":"34","author":"Ottenbourgs","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.gore.2026.102123_b0270","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3109\/01443615.2012.668579","article-title":"Safety of hormone replacement therapy in gynaecological cancer survivors","volume":"32","author":"Biliatis","year":"2012","journal-title":"J. Obstet. Gynaecol."},{"key":"10.1016\/j.gore.2026.102123_b0275","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3109\/13697137.2013.806471","article-title":"Estrogen therapy in gynecological cancer survivors","volume":"16","author":"Guidozzi","year":"2013","journal-title":"Climacteric"},{"key":"10.1016\/j.gore.2026.102123_b0280","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.maturitas.2016.07.018","article-title":"Menopausal hormone therapy in cancer survivors: a narrative review of the literature","volume":"92","author":"Kuhle","year":"2016","journal-title":"Maturitas"},{"key":"10.1016\/j.gore.2026.102123_b0285","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/GCO.0000000000000238","article-title":"Hormone replacement therapy after treatment for a gynaecological malignancy","volume":"28","author":"O\u2019Donnell","year":"2016","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"10.1016\/j.gore.2026.102123_b0290","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ygyno.2017.06.013","article-title":"Management of menopausal symptoms in women with gynecologic cancers","volume":"146","author":"Del Carmen","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2026.102123_b0295","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy001","article-title":"Non-epithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Ray-Coquard","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.gore.2026.102123_b0300","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S0140-6736(23)02802-7","article-title":"Managing menopause after cancer","volume":"403","author":"Hickey","year":"2024","journal-title":"Lancet"}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926001037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926001037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:05:35Z","timestamp":1781669135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578926001037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":60,"alternative-id":["S2352578926001037"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2026.102123","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Granulosa cell tumors and menopausal hormone therapy: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2026.102123","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102123"}}